No Data
CONSUN PHARMA (01681.HK): Yishen Huashi Granules approved as a secondary protection variety of Traditional Chinese Medicine.
On April 30th, Gelonghui reported that CONSUN PHARMA (01681.HK) announced that on April 28, 2025, the National Medical Products Administration released the "Announcement on Protected Traditional Chinese Medicine Varieties (No. 25) (2025 No. 45)", which listed the company's product, Yishen Huashi Granules ("the product"), which has been approved as a second-level protected variety of Traditional Chinese Medicine according to the "Regulations on the Protection of Traditional Chinese Medicine Varieties". The company's wholly-owned subsidiary, Guangzhou CONSUN PHARMA Co., Ltd. ("Guangzhou CONSUN"), was awarded the "Traditional Chinese Medicine Protection Variety Certificate" ("the certificate"), certificate number: (2025) National Medicine Zhongbao Letter No. 009. The product enjoys
CONSUN PHARMA: ANNUAL REPORT 2024
Consun Pharmaceutical Unit Gets China Nod for Renal Disease Drug Trial
CONSUN PHARMA: NOTICE OF ANNUAL GENERAL MEETING
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
CONSUN PHARMA (01681) received the "Drug Clinical Trial Approval Notification" for SK-09 tablets.
CONSUN PHARMA (01681) announced that the company has received the relevant SK-09 tablet issued by the National Medical Products Administration of China...
